With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.122-18-9,N-Benzyl-N,N-dimethylhexadecan-1-aminium chloride,as a common compound, the synthetic route is as follows.
EXAMPLE 4 N-(1H-pyrazol-1-ylmethyl)-N-(2,4-dimethyl-thien-3-yl)-chloroacetamide (process b) To a well stirred mixture of 19.35 g (0.095 mol) of N-(2,4-dimethyl-thien-3-yl)-chloroacetamide, 4.15 g (0.01 mol) of benzyldimethylhexadecyl-ammonium chloride, 40 g (1 mol) of sodium hydroxide, 200 ml of methylene chloride and 40 ml of water are added 17 g (0.11 mol) of solid 1-chloromethyl pyrazolehydrochloride at such a rate, that the temperature does not rise above 25. When the addition is completed, the reaction mixture is stirred an additional 21/2 hours at ambient temperature. Then 100 ml of water are added. The organic layer is separated, washed with three 200 ml portions of water, dried over Na2 SO4 and evaporated to dryness. The residue is chromatographed on a silica gel column. Elution with hexane-diethylether 1:1 affords the title compound as an analytically pure syrup which crystallized on chilling overnight at -20, m.p. 88-89 (recrystallized from diethyl ether).
As the paragraph descriping shows that 122-18-9 is playing an increasingly important role.
Reference£º
Patent; Sandoz Ltd.; US4666502; (1987); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI